KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) Interest & Investment Income: 2012-2024

Historic Interest & Investment Income for Travere Therapeutics (TVTX) over the last 13 years, with Dec 2024 value amounting to $17.8 million.

  • Travere Therapeutics' Interest & Investment Income fell 14.65% to $3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.9 million, marking a year-over-year decrease of 34.24%. This contributed to the annual value of $17.8 million for FY2024, which is 18.15% down from last year.
  • Travere Therapeutics' Interest & Investment Income amounted to $17.8 million in FY2024, which was down 18.15% from $21.8 million recorded in FY2023.
  • In the past 5 years, Travere Therapeutics' Interest & Investment Income ranged from a high of $21.8 million in FY2023 and a low of -$19.7 million during FY2021.
  • Its 3-year average for Interest & Investment Income is $15.3 million, with a median of $17.8 million in 2024.
  • Its Interest & Investment Income has fluctuated over the past 5 years, first spiked by 246.85% in 2023, then declined by 18.15% in 2024.
  • Yearly analysis of 5 years shows Travere Therapeutics' Interest & Investment Income stood at -$19.1 million in 2020, then declined by 3.32% to -$19.7 million in 2021, then soared by 131.89% to $6.3 million in 2022, then skyrocketed by 246.85% to $21.8 million in 2023, then dropped by 18.15% to $17.8 million in 2024.